RxLedger

Dificid (Fidaxomicin) — Medicare Part D spending

Merck Sharp & D · Rank #334 by total Part D spend · CMS data year 2023

Medicare Part D spent $127,162,103 on Dificid (Fidaxomicin) in 2023, the #334 drug by total Part D spending out of 3,598 drugs. That worked out to about $244.78 per dosage unit, $4,437 per claim and $5,898 per beneficiary, across 28,662 claims for 21,562 beneficiaries. Average spending per dosage unit rose +5.7% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Dificid (Fidaxomicin) spending at a glance (2023)

MetricDificid (Fidaxomicin)
Total Part D spending (2023)$127,162,103
Total spending (2022)$103,081,747
Year-over-year change in total spending+23.4%
Average spending per dosage unit (2023)$244.78
Change in spend per dosage unit (YoY)+5.7%
Avg annual change per dosage unit (2019-2023 CAGR)+5.5%
Average spending per claim (2023)$4,437
Average spending per beneficiary (2023)$5,898
Total claims (2023)28,662
Beneficiaries (2023)21,562
Total dosage units (2023)527,975
Manufacturer(s)Merck Sharp & D
National rank by total spend (of 3,598 drugs)#334

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Dificid (Fidaxomicin): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$103,081,747$127,162,103+23.4%
Avg spend per dosage unit$231.58$244.78+5.7%
Avg spend per claim$4,289$4,437
Avg spend per beneficiary$5,657$5,898
Total claims24,03528,662
Beneficiaries18,22121,562

How Dificid compares with nearby drugs

Drugs with total Part D spending closest to Dificid (Fidaxomicin):

Dificid (Fidaxomicin) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Dificid (Fidaxomicin) (this drug, #334)$127,162,103$244.78+5.7%
Orserdu (Elacestrant HCl) (#332)$127,626,022$694.68
Olanzapine* (Olanzapine) (#333)$127,379,077$1.00+3.3%
Nano 2nd Gen Pen Needle (Pen Needle, Diabetic) (#335)$127,016,041$0.54+3.1%
Gilenya (Fingolimod HCl) (#336)$125,490,483$356.52+6.4%
Skyrizi On-Body (Risankizumab-Rzaa) (#337)$125,306,777$9,002.43+13.5%

Frequently asked questions

How much does Medicare Part D spend on Dificid?

Medicare Part D spent $127,162,103 on Dificid (Fidaxomicin) in 2023 (the latest CMS data year), across 28,662 claims for 21,562 beneficiaries. That ranks #334 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Dificid?

In 2023, the weighted average Medicare Part D spending per dosage unit for Dificid (Fidaxomicin) was $244.78. Compared with 2022 it rose +5.7%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Dificid?

CMS attributes Dificid (Fidaxomicin) to Merck Sharp & D in the 2023 Part D spending file. Average spending per claim was $4,437 and per beneficiary $5,898.

Is the Dificid figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20